Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
作者信息
Kobayashi Takashi
机构信息
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
出版信息
Int J Urol. 2022 Jul;29(7):739. doi: 10.1111/iju.14919. Epub 2022 Apr 27.
Abstract
摘要
相似文献
1
Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.小林博士对尿路上皮癌和肾细胞癌患者中积极抗癌治疗对SARS-CoV-2 BNT162b2疫苗血清学反应的影响的编辑评论。
Int J Urol. 2022 Jul;29(7):739. doi: 10.1111/iju.14919. Epub 2022 Apr 27.
2
Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.汤浅博士对积极抗癌治疗对尿路上皮癌和肾细胞癌患者对SARS-CoV-2 BNT162b2疫苗血清学反应的影响的编辑评论。
Int J Urol. 2022 Jul;29(7):740. doi: 10.1111/iju.14920. Epub 2022 May 10.
3
Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.活性抗癌治疗对尿路上皮癌和肾细胞癌患者对 SARS-CoV-2 BNT162b2 疫苗血清反应的影响。
Int J Urol. 2022 Jul;29(7):733-739. doi: 10.1111/iju.14882. Epub 2022 Mar 31.
4
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.CoronaVac 加强针接种后对 SARS-CoV-2 抗体反应的动力学。
Emerg Infect Dis. 2022 Jun;28(6):1237-1240. doi: 10.3201/eid2806.220061. Epub 2022 Apr 14.
5
BNT162b2 mRNA COVID-19 Vaccine: First Approval.BNT162b2 mRNA COVID-19 疫苗：首次批准。
Drugs. 2021 Mar;81(4):495-501. doi: 10.1007/s40265-021-01480-7.
6
Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?BNT162b2疫苗的第二剂延迟接种：是创新还是错误的推测？
Lancet. 2021 Mar 6;397(10277):879-880. doi: 10.1016/S0140-6736(21)00455-4. Epub 2021 Feb 19.
7
Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.评估接受血液透析患者对 BNT162b2 疫苗的 SARS-CoV-2 抗体反应。
JAMA Netw Open. 2021 Sep 1;4(9):e2123622. doi: 10.1001/jamanetworkopen.2021.23622.
8
Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.科兴和国药疫苗及未感染过 SARS-CoV-2 医护人员与已感染过 SARS-CoV-2 医护人员接种后中和抗体滴度比较。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac010.
9
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
10
Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.影响实体瘤患者对 SARS-CoV-2 疫苗血清学反应的因素：一项前瞻性研究。
J Infect Chemother. 2022 Sep;28(9):1310-1316. doi: 10.1016/j.jiac.2022.05.021. Epub 2022 Jun 6.
本文引用的文献
1
Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.活性抗癌治疗对尿路上皮癌和肾细胞癌患者对 SARS-CoV-2 BNT162b2 疫苗血清反应的影响。
Int J Urol. 2022 Jul;29(7):733-739. doi: 10.1111/iju.14882. Epub 2022 Mar 31.
2
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.COVID-19 疫苗 BNT162b2 在接受实体瘤化疗患者中的安全性和免疫原性。
J Infect Chemother. 2022 Apr;28(4):516-520. doi: 10.1016/j.jiac.2021.12.021. Epub 2021 Dec 30.
3
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.接受癌症治疗的实体瘤患者接种 SARS-CoV-2 mRNA 疫苗后血清转换受损。
Eur J Cancer. 2022 Mar;163:16-25. doi: 10.1016/j.ejca.2021.12.006. Epub 2021 Dec 22.
4
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment.评估接受主动治疗的实体瘤患者对第三剂 SARS-CoV-2 BNT162b2 mRNA 疫苗的反应。
JAMA Oncol. 2022 Feb 1;8(2):300-301. doi: 10.1001/jamaoncol.2021.6764.
5
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.帕博利珠单抗治疗前中性粒细胞与淋巴细胞比值（NLR）可预测二线帕博利珠单抗治疗尿路上皮癌的疗效，而与化疗前 NLR 无关。
Cancer Immunol Immunother. 2022 Feb;71(2):461-471. doi: 10.1007/s00262-021-03000-8. Epub 2021 Jul 7.
Zotero 插件